Trinity Biotech (TRIB) Cash & Current Investments (2009 - 2025)

Trinity Biotech (TRIB) has reported Cash & Current Investments for 17 consecutive years, with $5.1 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Current Investments fell 32.59% year-over-year to $5.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 million (down 32.59% YoY) and the FY2025 annual result came in at $5.1 million, down 32.59% from the prior year.
• Cash & Current Investments fell to $5.1 million in Q4 2025 per TRIB's latest filing, from $7.9 million in the prior quarter.
• Over the last five years, Cash & Current Investments for TRIB reached as high as $32.3 million in Q1 2021 and fell as low as $2.8 million in Q3 2024.
• A 5-year average of $14.1 million and a median of $9.0 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments jumped 143.71% — and 2024, when it plunged 80.04%.
• Year by year, Cash & Current Investments stood at $25.9 million in 2021, then sank by 74.23% to $6.7 million in 2022, then sank by 41.73% to $3.9 million in 2023, then soared by 95.89% to $7.6 million in 2024, then plunged by 32.59% to $5.1 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $5.1 million, $7.9 million, and $7.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.